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Abstract
Introduction: To evaluate whether alkaline phosphatase (AP) treatment improves renal function in sepsis-induced
acute kidney injury (AKI), a prospective, double-blind, randomized, placebo-controlled study in critically ill patients
with severe sepsis or septic shock with evidence of AKI was performed.
Methods: Thirty-six adult patients with severe sepsis or septic shock according to Systemic Inflammatory Response
Syndrome criteria and renal injury defined according to the AKI Network criteria were included. Dialysis
intervention was standardized according to Acute Dialysis Quality Initiative consensus. Intravenous infusion of
alkaline phosphatase (bolus injection of 67.5 U/kg body weight followed by continuous infusion of 132.5 U/kg/24 h
for 48 hours, or placebo) starting within 48 hours of AKI onset and followed up to 28 days post-treatment. The
primary outcome variable was progress in renal function variables (endogenous creatinine clearance, requirement
and duration of renal replacement therapy, RRT) after 28 days. The secondary outcome variables included changes
in circulating inflammatory mediators, urinary excretion of biomarkers of tubular injury, and safety.
Results: There was a significant (P = 0.02) difference in favor of AP treatment relative to controls for the primary
outcome variable. Individual renal parameters showed that endogenous creatinine clearance (baseline to Day 28)
was significantly higher in the treated group relative to placebo (from 50 ± 27 to 108 ± 73 mL/minute (mean ±
SEM) for the AP group; and from 40 ± 37 to 65 ± 30 mL/minute for placebo; P = 0.01). Reductions in RRT
requirement and duration did not reach significance. The results in renal parameters were supported by
significantly more pronounced reductions in the systemic markers C-reactive protein, Interleukin-6, LPS-binding
protein and in the urinary excretion of Kidney Injury Molecule-1 and Interleukin-18 in AP-treated patients relative to
placebo. The Drug Safety Monitoring Board did not raise any issues throughout the trial.
Conclusions: The improvements in renal function suggest alkaline phosphatase is a promising new treatment for
patients with severe sepsis or septic shock with AKI.
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Introduction
Septic shock is the most common cause of acute kidney
injury (AKI) [1], and is associated with considerable
morbidity and mortality [2-4]. Currently, there is no sin-
gle drug approved for the treatment of sepsis-induced
AKI [5].
Alkaline phosphatase (AP) is an endogenous enzyme
that exerts detoxifying effects through dephosphoryla-
tion of endotoxins [6,7] and pro-inflammatory extracel-
lular ATP [8]. Local AP concentrations reflect the host
defense against endotoxin in the kidney [9], and during
ischemia enzyme levels are markedly depleted, asso-
ciated with the development of AKI [10]. Apart from
local effects in the kidney, AP may attenuate the innate
immune response, as dephosphorylation of endotoxin
abolishes its biological activity and induces tolerance to
subsequent endotoxin exposure [11]. In animal models
of sepsis, AP administration attenuates the inflammatory
response and reduces mortality [12,13].
In a previous trial investigating the safety and pharma-
cokinetics in patients with sepsis (with and without evi-
dence of AKI), Heemskerk et al. showed that
administration of AP was associated with a decreased
expression of inducible nitric oxide synthase in proximal
tubule cells isolated from urine related to an attenuated
urinary excretion of the proximal tubule injury marker
glutathione S-transferase A1-1 (GSTA1-1) [14]. How-
ever, this previous trial had not been powered to test
clinical renal endpoints, as it had also enrolled patients
without AKI. Therefore, the current prospective trial
focusing on severe sepsis patients or septic shock with
evidence of AKI was required to examine the effects of
AP on clinical renal endpoints, urinary excretion of var-
ious markers of tubular injury, and circulating inflam-
matory markers.
Materials and methods
Patient selection and design
All patients who were admitted to one of the seven par-
ticipating intensive care units (ICUs, three Dutch, four
Belgian) were enrolled from June 2008 to November
2009 after approval by the hospitals’ Ethics Committees,
national authorities and trial registration (NCT
00511186). Following written informed consent from
the subject or legal representative, patients with severe
sepsis or septic shock [15] and AKI who fulfilled the
protocol selection criteria (Table 1) were randomized in
a double-blind, placebo-controlled design. Treatment
consisted of an intravenous bolus injection of AP (calf
intestinal AP; AM-Pharma, Bunnik, The Netherlands)
67.5 U/kg bodyweight over 10 minutes followed by con-
tinuous infusion of 132.5 U/kg/24 h followed-up for 28
days post-entry.
Patients were randomly assigned in a 1:1 ratio to AP
or placebo. Study medication was packaged according to
a randomization list in blocks of four, labeled with sub-
ject number and additional administration information.
Each patient to be entered in the study was assigned the
next consecutive number. Both placebo and AP were
supplied as a clear, colorless, sterile, pyrogen-free solu-
tion in 10 mL type I glass vials with a Teflon-coated
bromobutyl rubber stopper and indistinguishable from
each other. The responsible pharmacist calculated the
exact volume of AP or placebo to be administered to
each patient based on body weight and treatment code.
The master randomization list was held by Choice
Pharma Ltd. 65 Knowl Piece Wilbury Way, Hitchin
Hertfordshire, SG4 0TY UK. Individual sealed envelopes
with the treatment code for each patient were filed in a
secure location at each hospital and at Choice Pharma
Ltd. 65. Data were entered into a clinical database by
CRM Biometrics (Boehringer Mannheim, Germany).
AKI was defined according to the Acute Kidney Injury
Network (AKIN) criteria [16] and the criteria for initia-
tion of RRT (in all cases continuous veno-venous hemo-
filtration, CVVH) were standardized per the Acute
Dialysis Quality Initiative (ADQI) consensus [17].
Apart from the safety endpoints required by regulatory
authorities for phase-II trials, the primary efficacy out-
come measure was a prospectively defined composite
end-point, including recovery of endogenous creatinine
clearance (eCrCl), the need for RRT throughout the 28-
day study period, and the total duration (hours on RRT
per total number of patients; cumulatively for multiple
interventions over the period). eCrCl was measured
every 24 h with the following formula: eCrCl (mL/min-
ute) = (Urine Creatinine (μM or mg/dL) × Volume
(mL))/(Serum Creatinine (μM or mg/dL) × Time
(minutes)
In addition, combinations of alternative parameters
were tested exploratorily (see Additional file 1).
The secondary endpoints were changes in the urinary
excretion of biomarkers of renal injury [18,19]: kidney
injury molecule-1 (KIM-1), neutrophil gelatinase-asso-
ciated lipocalin (NGAL), interleukin-18 (IL-18), glu-
tathione S-transferase (GST)A1-1 and GSTP1-1 (see
additional file 2); serum concentrations of lipopolysac-
charide-binding protein (LBP), IL-6, C-reactive protein
(CRP), and procalcitonin (PCT); changes in Sequential
Organ Failure Assessment (SOFA) score; duration of
ventilator support; length of ICU and hospital stay; and
all-cause mortality.
Safety was evaluated by adverse event (AE) monitoring
and any abnormalities during clinical management
throughout the trial, reported according to MedDRA
(Medical Dictionary for Regulatory Activities [20]), and
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overseen by an independent Data Safety Monitoring
Board (DSMB).
This trial was designed by P Pickkers and JG van der
Hoeven and approved by AM-Pharma. All investigators
were responsible for their own data collection. Statistical
analysis was conducted by an independent agency:
CRMB Biometrics GmbH, Boehringer Mannheim, Ger-
many (J Schmitz and J Hartung). AM-Pharma was not
involved in the interpretation of the data, in the pre-
paration of the manuscript or in the decision to submit
the manuscript for publication. The trial was funded by
a grant from AM-Pharma BV who provided active and
placebo AP enzyme.
Assays methodology
Arterial blood (arterial line, every 12 h) and urine
(indwelling catheter, every 6 h) were freshly collected
(and subsequently frozen at -80°C) during 48 h of treat-
ment and daily thereafter until Day 7. Urinary KIM-1,
NGAL, IL-18, GSTA1-1 and GSTP1-1 [18,19] were
assayed in duplicate by enzyme-linked immunosorbent
assay (ELISA), maximum intra- and interassay coeffi-
cient of variation (CV) of 10 and 15%, respectively (see
Additional file 2). Routine hematology, biochemistry and
CRP were evaluated by each hospital’s laboratory; PCT
was analyzed centrally at UMC Laboratories (Nijmegen,
The Netherlands); LBP and IL-6 were determined
Table 1 Patient entry selection
Inclusion criteria
• Age: 18 to 80 years, inclusive
• Diagnosis: proven or suspected infection
• Two out of four SIRS criteria of systemic inflammation [36]
- Core temperature > 38° or < 36° Celsius
- Heart rate > 90 beats/minute (unless the patient has a medical condition known to increase heart rate or is receiving treatment that
would prevent tachycardia)
- Respiratory rate > 20 breaths/minute, PaCO2 < 32 mmHg or the use of mechanical ventilation for an acute respiratory process
- White-cell count > 12,000/mm3 or < 4,000/mm3 or a differential count showing > 10% immature neutrophils.
• Acute Kidney Injury, defined as:
• Rise in serum creatinine level to > 150 μmol/L (1.70 mg/dL) within the previous 48 hours, in the absence of primary underlying renal disease,
OR
• Minimally at Stage 1 Kidney Injury according to AKIN creatinine criteria: Increase in serum creatinine > 26.2 μmol/L (0.30 mg/dL) or increase to
> 150% (> 1.5-fold) from baseline in the previous 48 hours in the absence of primary underlying renal disease and where baseline creatinine is
less than 150 μmol/L (1.70 mg/dL)), OR
• Minimally at Stage 1 Kidney Injury (AKIN) Urine Output criteria: Urine Output < 0.5 mL/kg/h for > 6 h and following adequate fluid
resuscitation when applicable, in the absence of underlying primary renal disease and where baseline creatinine is less than 150 μmol/L (1.70
mg/dL).
• Written informed consent obtained prior to any study intervention.
In addition to the above, acute onset of end-organ dysfunction (other than renal failure) in the preceding 12 hours unrelated to the primary
septic focus and not explained by any underlying chronic disease [15]may be present (not compulsory) for patient qualification for enrollment)
Exclusion criteria
• Pregnant women or nursing mothers and fecund females not on effective contraception
• Known HIV (sero-positive) patients
• Patients already on RRT at entry
• Patients receiving immunosuppressant therapy or on chronic high doses of steroids equivalent to prednisone 1 mg/kg/day
• Patients expected to have rapidly fatal disease within 24 hours
• Known confirmed gram-positive sepsis
• Known confirmed fungal sepsis
• Acute pancreatitis with no established source of infection
• Any previous administration of exogenous AP
• Participation in another investigational study within 90 days
• Patients not expected to survive for 28 days due to other medical conditions such as end-stage neoplasm
• Known allergy to dairy products including cow milk
• Sepsis without renal failure as defined in Entry Criteria
• History of chronic renal failure or history of persistent creatinine level equal or greater than 150 μmol/L (1.70 mg/dL) prior to entry for reasons
other than the current sepsis condition
AP, alkaline phosphatase; PaCO2, partial arterial pressure of carbon dioxide; RRT, renal replacement therapy; SIRS, systemic inflammatory response syndrome.
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centrally by TNO Quality of Life Laboratories (Zeist,
The Netherlands).
Statistics
The intention-to-treat (ITT) population was used for
efficacy evaluations, per prospective Statistical Plan.
Since the variation of the combined clinical renal end-
points in septic patients is unknown, the hypothesis
assumed a standardized difference of 1.0 (mean treat-
ment difference/SD), with 80% power and alpha at 5%
(two-sided), which required at least 17 patients per
treatment group. Appropriate methodology was applied
to the data regarding testing for distribution, including
application of central limit theorem [21] where para-
metric tests were applied to non-normally distributed
data. The primary efficacy measure of combined renal
parameters was calculated according to the method of
Hartung [22]; eCrCl was analyzed by repeated measures
ANOVA, RRT requirement by Fisher’s exact test, and
RRT duration by t-test. For eCrCl, missing values (typi-
cally after Day 7, due to ICU discharge) were imputed
from last-observation-carried forward (LOCF). Systemic
and urinary biomarkers were analyzed by repeated mea-
sures ANOVA with baseline concentrations as covariate.
Safety variables were compared using Fisher’s exact test.
Analysis was performed using SAS version 9.2 (SAS
Institute Inc, Cary, NC, USA).
Results
The two treatment groups (flow chart illustrated in Fig-
ure 1) were well-balanced at entry and there were no
significant differences regarding baseline parameters
(Table 2). At baseline, 94% patients in the AP group
and 89% patients in the placebo group (P = 0.31) ful-
filled the criteria for septic shock (mean arterial pressure
(MAP) ≤70 mmHg for at least one hour despite ade-
quate fluid intake, or requirement for vasopressor sup-
port to maintain MAP). All patients were diagnosed
with AKI according to the AKIN creatinine criteria or
rise in serum creatinine level to > 150 μmol/L (1.70 mg/
dL) within the previous 48 h. Furthermore, at baseline,
there were eight anuric/oliguric (oliguria < 0.3 mL/Kg/h
for > 6 h and serum urea > 20 mmol/L) patients in the
placebo group (42%) and five anuric/oliguric patients in
the AP group (31%, P = 0.14). One patient received
study treatment (placebo) for less than one hour and
had no efficacy evaluations beyond baseline. The deci-
sion to exclude this patient from the efficacy analyses
was made blindly at the end of the trial, before code
break. This patient was included in the safety analysis
(conducted on all patients who took any study drug).
Renal variables
The primary efficacy variable (renal parameters) showed
a better outcome in the AP group (P = 0.02, Figure 2).
The differences were maintained during exploratory
analyses using other possible combinations of relevant
renal parameters (see Additional file 1). Individually, the
recovery of eCrCl was significantly more pronounced in
the AP-treated group compared to the placebo-group
during the first seven days, and this effect was sustained
throughout the 28-day period (P = 0.01). In addition,
regression analysis of eCrCl values excluding patients on
RRT confirmed a significant (P < 0.03) and progressive
effect of AP on clearance levels up to Day 7 post-entry
(data not shown). Start of RRT, according to ADQI
Figure 1 Flow chart of patients.
Pickkers et al. Critical Care 2012, 16:R14
http://ccforum.com/content/16/1/R14
Page 4 of 12
consensus criteria, was between one to three days after
entry in all but two cases (one case in each treatment
group). Patients who did not receive RRT were assigned
zero days of RRT. RRT requirement was not different
between both groups (Figure 1, P = 0.29), while RRT
duration tended to be shorter in the AP group (P =
0.08). The effects of AP were similar in patients with or
without proven Gram-negative infections (data not
shown).
Secondary efficacy parameters
Urinary biomarkers of renal injury
During the course of the study, the decline of the urin-
ary excretion of KIM-1 and IL-18 was significantly more
pronounced in the AP group relative to placebo, while
NGAL and GST enzymes were not significantly different
(Figure 3).
Serum concentrations of inflammatory markers
The decline in CRP, LBP and IL-6 levels was signifi-
cantly more pronounced in the AP group, while PCT
was not significantly different (Figure 4).
Clinical management parameters
Decrease in SOFA score evaluated during ICU stay was
not significantly different between groups (see Addi-
tional file 3 for tabulated results of secondary clinical
parameters). The reduction in total SOFA score was
mainly caused by an improvement of kidney function.
No relevant effects of AP on the other SOFA parameters
were found. Length of stay in ICU was 25 ± 18 days for
placebo and 11 ± 8 days for AP (P < 0.02). Total length
of hospital stay was 31 ± 26 days on AP and 47 ± 36
days on placebo (P = 0.14).
The 28-day overall mortality after inclusion in the AP
group was 7/16, compared with 6/20 in the placebo
group (Log rank test, P = 0.25). All deaths were attribu-
ted to the underlying condition by the attending physi-
cians and were subsequently reviewed by DSMB.
Safety results
The incidence and type of AEs, serious and non-serious,
were as expected for this population (Table 3). The inci-
dence of treatment-emergent AEs was similar for the
two treatment groups (AP: 124 events/16 patients; pla-
cebo: 147 events/20 patients). The independent DSMB
did not raise any safety concerns during the trial.
Discussion
In this prospective, randomized, double-blind, placebo-
controlled phase-II trial in patients with severe sepsis or
septic shock and evidence of AKI, administration of exo-
genous AP enzyme was shown to improve overall renal
function, based on endogenous creatinine clearance,
requirement and duration of renal replacement therapy.
The latter were in line with urinary excretion of some
markers of renal injury and with serum markers of sys-
temic inflammation. By focusing our evaluations on
patients with AKI secondary to sepsis, our results com-
plement and expand our knowledge of the effects of AP
previously reported in a general population of sepsis
patients with and without AKI [14]. To the best of our
Table 2 Analysis sets and patients’ characteristics at entry
Baseline Parameter* AP
(n = 16)
Placebo (n = 19) P =
Male: n (%) 13 (81) 14 (74) 0.7003†
Age: mean (SD) years 65 (12) 67 (15) 0.7323‡
Height: mean (SD) cm 176 (10) 174 (8) 0.6275‡
Weight: mean (SD) kg 86 (12) 80 (14) 0.2207‡
Heart rate: mean (SD) bpm 103 (23) 105 (22) 0.8510‡
Systolic BP: mean (SD) mmHg 103 (26) 110 (26) 0.4140‡
Diastolic BP: mean (SD) mmHg 52 (13) 55 (13) 0.4035‡
Temperature: mean (SD) °C 37 (1) 37 (1) 0.5899‡
APACHE-II score: mean (SD) 24 (7) 23 (8) 0.5928‡
SOFA score: mean (SD) 10 (4) 11 (5) 0.9128‡
AKIN stage 1: % 44 58 0.0657†
AKIN stage > 1: % 56 42
Urine production: mean (SD) mL/kg/hour 0.6 (0.4) 0.6 (0.7) 0.9245‡
Serum creatinine: mean (SD) μmol/L 164 (48) 214 (120) 0.1108‡
Creatinine clearance: mean (SD) mL/minute 50 (27) 40 (37) 0.3984‡
(Nor)epinephrine: mean (SD; n) μg/kg/min 0.32 (0.25;13) 0.40 (0.28;15) 0.3418‡
Dopamine/dobutamine: mean (SD; n) μg/kg/min 1.50 (2.12;2) 0.25 (0.35;2) 0.4975‡
* No significant differences between groups at baseline. †Fishers’s exact test and ‡ t-test for two independent groups was used. All patients were Caucasians.
AKIN, Acute Kidney Injury Network; APACHE-II, Acute Physiology and Chronic Health Evaluation-II; CONSORT, Consolidated Standards of Reporting Trials; SD,
standard deviation; SOFA, Sequential Organ Failure Assessment.
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Figure 2 Progression of renal parameters. (A) Endogenous creatinine clearance is expressed as mean ± SEM (one-side depicted) and analyzed
by ANOVA with repeated measurements over the complete curve (P = 0.01). Missing values were imputed from last-observation-carried forward
(LOCF) from Day 7 to Day 28. (B) Renal replacement therapy (RRT) requirement is expressed as percentage in total treatment group; analyzed by
Fisher’s exact test (P = 0.29). (C) RRT duration: hours per total number of patients in group (cumulative for multiple interventions) over study period,
expressed as mean ± SEM; analyzed by independent t-test (P = 0.08). *: Primary variable analyzed by the Hartung method [22].
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knowledge, this is the first clinical trial in critically ill
adults with sepsis that investigates measures of renal
function combined with a panel of urinary biomarkers
of renal injury. We found significant differences between
treatment groups for KIM-1 and IL-18 excretion, both
described to have prognostic importance for RRT
requirement and mortality in patients with AKI [18,23].
Urinary excretion of other markers showed similar
trends that did not reach significance likely due to a
large variance between patients and inadequate power.
For example, NGAL also showed a significant decrease
in the AP-treated patients, while no change was
observed in the placebo-treated patients. Because of the
fact that the baseline values of NGAL were higher in
Figure 3 Urinary biomarkers of renal injury. (A) Kidney injury molecule-1 (KIM-1); (B) neutrophil gelatinase-associated lipocalin (NGAL); (C)
glutathione S-transferase A1-1 (GSTA1-1); (D) GSTP1-1; and (E) IL-18 levels in urine; measured at various times points for placebo and alkaline
phosphatase treatment during the first seven days. Urinary excretion of KIM-1 and IL-18 was lower in AP-treated patients relative to placebo-
treated patients. Data are expressed as mean ± SEM (one-side depicted) and analyzed by ANOVA with repeated measurements over the
complete curve with baseline as covariate.
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the AP-group, this difference between groups did not
reach significance. Apart from variance and the small
patient groups, power was further attenuated by the fact
that not all markers could be determined in all samples
because of limited urine volume.
Animal experiments indicate that the dephosphorylat-
ing enzyme AP is depleted in the kidney following an
ischemic insult [10]. Pharmacological restoration of
endogenous AP levels in the kidney may prevent further
renal damage or improve renal recovery, for which pos-
sible mechanisms include dephosphorylation of extra-
cellular ATP. Extracellular ATP released from necrotic
cells may directly activate the Nrlp3 inflammasome
through the P2X7 receptor and co-stimulation by reac-
tive oxygen species (ROS) or lipopolysaccharide (LPS)
[24]. Alkaline phosphatase dephosphorylation of ATP
and LPS results in reduced activation of the Nrlp3
inflammasome. As a consequence, the secretion of the
pro-inflammatory cytokines is reduced, leading to less
neutrophil infiltration in renal tissue, with lower local
and systemic inflammatory response [25]. Dephosphory-
lation of extra-cellular ATP locally also results in higher
levels of adenosine which, upon binding to its receptor,
exerts potent anti-inflammatory and renal tissue protec-
tive effects [26,27]. The combined effect of modulation
of local ATP and adenosine by AP results in reduced
tissue damage, and the significantly faster reduction of
the injury markers KIM-1 and IL-18 found in our trial
corroborate this mechanism. Extracellular ATP levels
are controlled by AP and other ectonucleotidases that
are expressed along the renal arterioles and tubules [28].
The importance of ATP metabolizing enzymes is
demonstrated by the finding that 5’ ectonucleotidase
(5’NT, or CD73) and NTDPase1 (CD39) provide protec-
tion against AKI in animal models [29,30]. The close
structural and functional relationships between alkaline
Figure 4 Systemic inflammatory markers. (A) LBP: Lipopolysaccharide-binding protein; (B) IL-6: interleukin-6; (C) CRP: C-reactive protein; (D)
PCT: procalcitonin. Data are expressed as mean ± SEM (one-side depicted); analyzed by ANOVA with repeated measurements over the complete
curve with baseline as covariate.
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phosphatase and other ectonucleotidases and their ther-
apeutic effect suggest that their modes of action may be
similar.
Apart from local effects in AP-depleted kidneys, it is
also thought that AP binds and detoxifies endotoxin
that may be present in the blood stream [11], thereby
modulating the inflammatory cascade in patients with
sepsis, which may eventually result in less organ
damage. We found a more pronounced decline in the
systemic inflammatory parameters CRP, LBP and IL-6
which are known to be induced by endotoxin in patients
treated with AP relative to controls [31]. This finding is
in agreement with animal experiments [13], but was not
found during experimental human endotoxemia using
AP [32] or during the previous trial in patients with sep-
sis [14]. The large inter-individual variation in inflam-
matory markers during experimental human
endotoxemia or in septic patients may account for this.
In the present study we studied a more homogeneous
group of severe sepsis or septic shock patients with AKI,
while in the previous trial patients with sepsis with and
without AKI were enrolled [14]. Since endotoxin is only
present in Gram-negative bacteria and because of the
putative relevance of AP-related detoxification of endo-
toxin, both completed phase-II trials in septic patients
aimed to exclude Gram-positive sepsis. Nevertheless,
almost half of enrolled patients did not show evidence
of Gram-negative infections. Of interest, we found the
beneficial renal effects of AP to be similar in patients
with or without proven Gram-negative infections, but
this does not exclude endotoxin detoxification being an
important mechanism by which AP protects the kidneys.
Indeed, in humans with severe sepsis or septic shock,
increased circulating concentrations of endotoxin have
been found in primary infections with both Gram-posi-
tive and Gram-negative bacteria [33]. Apparently, the
primary infection is not a major determinant of
increased circulating endotoxin levels in these patients,
as intestinal translocation of endotoxin may also play a
role [34]. In the present study we did not measure
blood endotoxin levels, but we found that the kinetics of
LBP was similar in patients with and without Gram-
negative infections, and that the decline of LBP levels
was significantly more pronounced in AP-treated
patients. Thus, detoxification of endotoxin by AP may
also contribute to the observed beneficial effects regard-
less of the primary bacterial pathogen. The observed
effects of AP on the course of inflammatory biomarkers
in the plasma suggest that AP exerts anti-inflammatory
effects (possibly by detoxifying LPS); however, a direct
effect of AP on the kidneys may also result in a swifter
normalization of the circulating inflammatory
biomarkers
There are several limitations of our study. First, the
overall sample size was small. Availability of safe bovine
AP enzyme and financial considerations were the main
reasons for the small sample. The small number of
adverse effects implicate that our study was not powered
to detect differences in safety measures. Importantly,
despite the latter and the heterogeneity of patients
Table 3 Safety results
AP Placebo
All adverse events (AEs) n
(%)
130 (100) 154 (100)
Treatment-emergent AEs* n
(%)
124 (95) 147 (96)
Patients with treatment-emergent
AEs
n
(%)
15/16
(94)
20/20
(100)
Non-serious treatment-emergent
AEsa:
n
Atrial fibrillation 3 6
Diarrhea 6 3
Hypotension 2 7
Delirium 2 5
Decubitus ulcer 1 4
Abdominal pain 3 2
Pyrexia 1 4
Impaired gastric emptying 3 2
Tracheostomy 1 3
Constipation 1 3
Restlessness 2 2
Atrial flutter 1 3
All serious treatment-emergent AEs n
Septic shock 2 2
Respiratory failure 3 1
Gastrointestinal necrosis 2 .
Hypotension . 2
Hepatic necrosis 1 .
Gall bladder necrosis 1 .
Electrolyte imbalance 1 .
Azotemia 1 .
Cardiac arrest . 1
Bradycardia . 1
Electrocardiogram QT prolonged . 1
Blood calcium decreased . 1
Coma . 1
Hyperlactacidemia . 1
Depressed level of consciousness . 1
Osteomyelitis 1 .
Brain neoplasm . 1
Renal failure . 1
Therapy cessation 1 .
Echocardiogram abnormal 1 .
AP, alkaline phosphatase.
*There were no treatment differences between the study groups regarding
the number of Treatment-emergent AEs per patient (Fisher’s exact test: P =
0.9089).
a: > 4 reported events in total.
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presenting with severe sepsis or septic shock, the
remarkable consistency of findings in this trial
(attenuation of urinary excretion of markers of renal
damage and improved clinical outcomes), and in the
previous trial in sepsis patients [14], suggest a strong
signal that demands further study. The effects on
eCrCl are likely to result in a beneficial effect on the
need for RRT when tested in a larger trial. Neverthe-
less, we acknowledge that small differences in, for
example, baseline creatinine may be responsible for
some of the differences in outcome measures and this
represents a limitation of the small study size. The
enrollment criteria applied in this study may have
resulted in inclusion of patients with AKI who were
within their therapeutic window of opportunity. It is
plausible that in previous studies [5,35] in which other,
possibly effective, pharmacological interventions were
tested in AKI, patients were enrolled in whom renal
damage was beyond repair. The results of the two
trials with bovine-origin AP enzyme and the restric-
tions of using bovine protein, indicate the need to
develop a human recombinant AP and to evaluate its
effects in clinical trials. Further trials should be con-
ducted with caution and include sufficient interim ana-
lyses to determine if the AP treatment worsens
mortality, irrespective of its impact on renal function.
A second issue that may need further explanation is
the fact that we calculated the eCrCl for all patients,
including those on RRT. We found that eCrCl was
restored to normal range in the AP group within the
first seven days, while it remained impaired in the pla-
cebo group. Although eCrCl calculations may overesti-
mate the recovery of renal function in the non-steady-
state period, the improvements in eCrCl were sustained
during the whole study and remained significantly
superior on AP treatment relative to placebo throughout
the 28-day period. We are confident that the renal
replacement therapy used in our study did not unduly
or significantly influence eCrCl evaluations, and it was
associated with stable, albeit lower serum creatinine
values throughout the intervention period, although any
such interference would have benefitted the control
group which required proportionally more RRT inter-
ventions. Importantly, a sensitivity analysis excluding
patients on RRT confirmed that CVVH did not signifi-
cantly influence the interpretation of creatinine clear-
ance data. Finally, one could argue that subjectivity of
the chosen parameters for the primary efficacy variable
of combined renal parameters (eCrCl, RRT requirement
and duration) could influence the conclusions. For this
reason, combinations of alternative parameters were
tested exploratorily (see Additional file 1) and the bene-
ficial effects of AP were shown to be maintained or
further enhanced. The effects on eCrCl are likely to
result in a beneficial effect on the need for RRT when
tested in a larger trial.
Conclusions
In septic patients with evidence of acute kidney injury,
treatment with alkaline phosphatase improved overall
renal function as represented by three main clinical
parameters: endogenous creatinine clearance, require-
ment and duration of dialysis. The course of biomarkers
of renal injury and systemic inflammation, as well as the
clinical progression, corroborate the observed beneficial
effects on renal function. These results suggest alkaline
phosphatase treatment may be efficacious for these
patients and a larger trial, preferably with recombinant
human AP, is needed to further investigate these
findings.
Key messages
• Alkaline phosphatase is an endogenous enzyme
that exerts detoxifying effects through dephosphory-
lation of endotoxins and pro-inflammatory extracel-
lular ATP.
• Administration of bovine alkaline phosphatase to
sepsis patients attenuates the urinary excretion of
markers of tubular injury.
• In the present randomized, double-blind placebo-
controlled phase 2 trial in patients with severe sepsis
or septic shock with evidence of acute kidney injury
treatment with alkaline phosphatase improved over-
all renal function as represented by three main clini-
cal parameters: endogenous creatinine clearance,
requirement and duration of dialysis.
• The results in renal parameters were supported by
more pronounced reductions in circulating inflam-
matory markers and in the urinary excretion of mar-
kers of tubular injury in AP-treated patients relative
to placebo.
Additional material
Additional file 1: Results of exploratory analyses of renal
parameters [37].
Additional file 2: Methods for biomarkers of renal injury.
Additional file 3: Results of secondary clinical parameters (non-
renal).
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